DRG Epidemiology's coverage of sepsis comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the incidence of sepsis for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's sepsis forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of sepsis over the forecast period?
- Of all people diagnosed with sepsis, how many in each country across the mature pharmaceutical markets are drug-treated?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following sepsis patient populations:
- Diagnosed events.
- Diagnosed events by severity.
- Severe sepsis by primary site of infection.
- Severe sepsis by pathogen.
Note: coverage may vary by country and region.
- Sepsis - Epidemiology - Mature Markets Data
- Key Findings
- Event Rate of Sepsis per 1,000 Among People of All Ages in 2016 and 2026
- Relative Sizes of Contributing Factors to the Trend in Events of Sepsis over the Next Ten Years
- Analysis of Diagnosed Events of Severe Sepsis by Pathogen
- Key Findings
- Epidemiology Data
- Diagnosed Events
- Primary Site of Infection of Severe Sepsis
- Drug Treatment
- Severe Sepsis Cases by Pathogen
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Sepsis
- Studies Excluded from the Analysis of Sepsis
- Risk/Protective Factors
- Risk/Protective Factors for Sepsis
- Literature Review
Author(s): Amy Bradshaw Kaiser, MS; Lade Ayodele
Amy Kaiser joined Decision Resources Group as an associate epidemiologist in 2017. Her focus is on the epidemiology of infectious diseases and niche and rare diseases.
She holds an MS in Epidemiology from the University of Massachusetts, Amherst and a BA in International Relations from Mount Holyoke College. Prior to joining Decision Resources Group, she worked as a human health research associate at a environmental consulting firm where her epidemiology research focused on occupational and environmental exposures and associated outcomes.
Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.
Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.